What is B. Riley's Forecast for MediciNova Q2 Earnings?

MediciNova, Inc. (NASDAQ:MNOV - Free Report) - Analysts at B. Riley issued their Q2 2025 earnings estimates for shares of MediciNova in a report issued on Monday, June 16th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings per share of ($0.07) for the quarter. B. Riley has a "Strong-Buy" rating and a $5.00 price objective on the stock. The consensus estimate for MediciNova's current full-year earnings is ($0.24) per share. B. Riley also issued estimates for MediciNova's Q3 2025 earnings at ($0.08) EPS and Q4 2025 earnings at ($0.10) EPS.

MediciNova (NASDAQ:MNOV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08.

A number of other equities analysts have also commented on MNOV. D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of MediciNova in a research note on Wednesday, April 9th. Wall Street Zen assumed coverage on MediciNova in a report on Sunday, May 18th. They issued a "hold" rating for the company.

MediciNova Stock Performance

Shares of NASDAQ MNOV traded up $0.02 during mid-day trading on Tuesday, hitting $1.29. 11,758 shares of the stock were exchanged, compared to its average volume of 37,462. MediciNova has a twelve month low of $1.12 and a twelve month high of $2.55. The stock's fifty day simple moving average is $1.43 and its two-hundred day simple moving average is $1.68. The company has a market cap of $63.27 million, a P/E ratio of -5.61 and a beta of 0.42.

Institutional Trading of MediciNova

Several hedge funds have recently modified their holdings of the stock. Jane Street Group LLC raised its position in MediciNova by 64.5% in the 4th quarter. Jane Street Group LLC now owns 23,259 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 9,121 shares during the last quarter. Millennium Management LLC increased its stake in shares of MediciNova by 26.7% in the 4th quarter. Millennium Management LLC now owns 25,923 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 5,470 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of MediciNova in the 4th quarter valued at $78,000. SBI Securities Co. Ltd. bought a new stake in shares of MediciNova during the fourth quarter worth $113,000. Finally, Barclays PLC lifted its stake in shares of MediciNova by 15.5% during the fourth quarter. Barclays PLC now owns 95,600 shares of the biopharmaceutical company's stock valued at $201,000 after acquiring an additional 12,800 shares during the period. 9.90% of the stock is owned by institutional investors.

MediciNova Company Profile

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.